The exceptions that prove the rule—a historical view of bedaquiline susceptibility

Abstract

Abstract In the accompanying study, Nimmo and colleagues estimated the dates of emergence of mutations in mmpR5 (Rv0678), the most important resistance gene to the anti-tuberculosis drug bedaquiline, in over 3500 geographically diverse Mycobacterium tuberculosis genomes. This provided important insights to improve the design and analysis of clinical trials, as well as the World Health Organization catalogue of resistance mutations, the global reference for interpreting genotypic antimicrobial susceptibility testing results.

Keywords

• Mycobacterium tuberculosis
• Bedaquiline susceptibility
• Resistance mutations
• Clinical trials